

You are cordially invited to attend a peer-to-peer presentation

Andexxa[®]

(coagulation factor Xa (recombinant), inactivated-zhzo)

Presented by: Benjamin Kalsmith, MD, FACC
Cardiovascular Disease Specialist
UPMC Shadyside

Hosted by: Sean Pines
717-319-1087
spines@portola.com

REGISTER TODAY!

Please register by going to: www.hlxregister.com

Please reference program code: **TYVVLX**

Program Details

Date: Saturday, September 26, 2020

Time: 12:15 PM ET

Andexxa Promotional Program Overview

- Burden of life-threatening bleeds related to FXa inhibitors
- Review the indications, mechanism, efficacy and safety of Andexxa for the reversal of FXa inhibitors rivaroxaban and apixaban

Please see Important Safety Information, including Boxed Warning below, and full Prescribing Information at: <https://www.andexxa.com/prescribing-information/>

INDICATION AND SELECT IMPORTANT SAFETY INFORMATION

WARNING: THROMBOEMBOLIC RISKS, ISCHEMIC RISKS, CARDIAC ARREST, AND SUDDEN DEATHS

See full prescribing information for complete boxed warning

Treatment with ANDEXXA has been associated with serious and life-threatening adverse events, including:

- Arterial and venous thromboembolic events
- Ischemic events, including myocardial infarction and ischemic stroke
- Cardiac arrest
- Sudden deaths

Monitor for thromboembolic events and initiate anticoagulation when medically appropriate. Monitor for symptoms and signs that precede cardiac arrest and provide treatment as needed.

INDICATION

ANDEXXA, coagulation factor Xa (recombinant), inactivated-zhzo is indicated for patients treated with rivaroxaban and apixaban, when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.

This indication is approved under accelerated approval based on the change from baseline in anti-FXa activity in healthy volunteers. An improvement in hemostasis has not been established. Continued approval for this indication may be contingent upon the results of studies to demonstrate an improvement in hemostasis.

Limitation of Use:

ANDEXXA has not been shown to be effective for, and is not indicated for, the treatment of bleeding related to any FXa inhibitors other than apixaban and rivaroxaban.

Important Safety Information continued on reverse side.

This program is sponsored by Portola Pharmaceuticals. In accordance with PhRMA Code on Interactions with Health Care Professionals, attendance at this educational program is limited to health care professionals. Attendance by guests or spouses is not appropriate and cannot be accommodated.

Andexxa[®]
Coagulation Factor Xa
(Recombinant), Inactivated-zhzo

PP-AnXa-US-0059